摘要
目的探讨脏毒清方联合XELOX化疗对结肠癌术后患者的疗效。方法选取60例结肠癌术后患者,按随机数字表法分为两组,各30例。两组均行手术治疗,对照组术后采用XELOX化疗方案,观察组在对照组基础上加用脏毒清方治疗,持续用药4个周期。比较两组肿瘤标志物水平、免疫功能、生存质量及不良反应情况。结果观察组治疗后癌胚抗原(CEA)、糖类抗原199(CA199)、肿瘤相关黏液抗原(CA242)、结肠癌特异性抗原-2(CCSA-2)水平分别为(13.54±1.49)μg/mL、(41.25±4.13)μg/mL、(30.11±3.85)IU/mL、(60.33±5.56)ng/mL,低于对照组的(17.49±1.58)μg/mL、(48.69±4.25)μg/mL、(36.15±3.91)IU/mL、(68.77±6.14)ng/mL,有统计学差异(P<0.05);观察组治疗后CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)为(64.63±6.15)%、(39.19±3.44)%、(1.68±0.29),高于对照组的(57.79±6.04)%、(32.88±3.37)%、(1.26±0.25),CD8^(+)为(23.35±2.41)%,低于对照组的(26.16±2.45)%,有统计学差异(P<0.05);观察组治疗后生理、心理、社会及环境领域评分为(86.97±6.12)分、(85.74±6.18)分、(89.74±5.12)分、(91.52±4.12)分,高于对照组的(80.41±6.05)分、(80.11±6.12)分、(82.36±5.48)分、(84.36±5.27)分,不良反应发生率低于对照组,有统计学差异(P<0.05)。结论脏毒清方联合XELOX化疗方案可提高结肠癌术后治疗效果,加快肿瘤标志物水平复常,促进免疫功能恢复,减少不良反应发生,改善患者生存质量。
Objective To investigate the effect of Zanduqingfang combined with XELOX chemotherapy in patients with colon cancer after operation.Methods 60 patients with postoperative colon cancer were selected and divided into 2 groups according to the random number table,30 patients in each group.Both groups were treated with surgery.The control group was treated with XELOX chemotherapy after surgery,and the observation group was treated with Zanduqingfang on the basis of the control group for 4 cycles.The levels of tumor markers,immune function,quality of life and adverse reactions were compared between the 2 groups.Results The levels of carcinoembryonic antigen(CEA),carbohydrate antigen 199(CA199),tumor associated mucus antigen(CA242)and colon cancer specific antigen 2(CCSA-2)in the observation group after treatment were(13.54±1.49)μg/mL、(41.25±4.13)μg/mL,(30.11±3.85)IU/mL,(60.33±5.56)ng/mL,lower than(17.49±1.58)in the control groupμg/mL、(48.69±4.25)μg/mL,(36.15±3.91)IU/mL,(68.77±6.14)ng/mL,with statistical difference(P<0.05);After treatment,CD3^(+),CD4^(+),CD4^(+)/CD8^(+)in the observation group were(64.63±6.15)%,(39.19±3.44)%,(1.68±0.29)%,higher than those in the control group(57.79±6.04)%,(32.88±3.37)%,(1.26±0.25),and CD8^(+)was(23.35±2.41)%,lower than those in the control group(26.16±2.45)%,with statistical difference(P<0.05);After treatment,the scores of physiological,psychological,social and environmental fields in the observation group were(86.97±6.12),(85.74±6.18),(89.74±5.12)and(91.52±4.12),which were higher than those in the control group(80.41±6.05),(80.11±6.12),(82.36±5.48)and(84.36±5.27).The incidence of adverse reactions was lower than that in the control group(P<0.05).Conclusion Zanduqingfang combined with XELOX chemotherapy regimen can improve the postoperative therapeutic effect of colon cancer,accelerate the normalization of tumor marker level,promote the recovery of immune function,re-duce adverse reactions,and improve the quality of life of patients.
作者
韩海涛
张双喜
郭海霞
安永康
张琳菡
刘晓博
屈海涛
HAN Haitao;ZHANG Shuangxi;GUO Haixia(The First Affiliated Hospital of Henan University of Traditional Chinese Medicine,Zhengzhou,450000)
出处
《实用癌症杂志》
2023年第7期1177-1180,共4页
The Practical Journal of Cancer
基金
河南省中医药科学研究专项课题(编号:20-21ZY2180)。
关键词
结肠癌
脏毒清方
化疗
免疫功能
肿瘤标志物
不良反应
Colon cancer
Zanduqingfang
Chemotherapy
Immunity
Tumor markers
Adverse reactions
